While the field of regenerative medicine has shown significant promise, materials are inherently fragile and more at risk than other products during the supply chain process. Cross-contamination, orientation and handling problems, and equipment failure all have potential to damage irreplaceable materials. To avoid this, traceability, along with efficient data management, is imperative and can be addressed using Chain of ComplianceTM processes. While few industry-wide standards currently exist, the industry can expect new regulations in nine areas, which are outlined in this white paper. Seven steps that companies should take now to ensure future compliance are also outlined.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.
Please enter the phone number you would like to be contacted at.